LONDON (Dow Jones)--ReGen Therapeutics Plc (RGT.LN) said Monday revenue for the first half of 2010 is estimated to be GBP132,000 compared with total revenues in 2009 of GBP56,055. MAIN FACTS: -This revenue has come from several of the markets where Colostrinin is now on sale and we look to continue this upward trend. -Company's Turkish licensee Eczacibasi Ilac Pazarlama A.S confirmed that it has launched ReGen's nutritional supplement Colostrinin under the local trade name Dyna in the Republic of Turkey. -Revenue to ReGen from Eczacibasi pursuant to the minimum annual purchase commitments in the distribution agreement is estimated to be $52,000 in the first year and $104,000 in the second year. -A combination of fundraising and sales with continuing attention to costs has improved the company's financial position since the year end. -Shares of ReGen at 1036 GMT up 0.13 pence or 5.3%, at 2.5 pence, valuing the company at GBP1.5 million. -By Tapan Panchal, Dow Jones Newswires. Tel +44(0)207-842 9448, tapan.panchal@dowjones.com (END) Dow Jones Newswires June 28, 2010 06:38 ET (10:38 GMT)